Loading viewer...
investor_presentation
Format: PDF investor_presentation
First Quarter 2022 Supplemental Financial Information April 28, 2022
Supplemental Financial
This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2022
guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including the projected impact of the
COVID-19 pandemic on the company’s businesses, operating results, cash flows and/or financial condition, as well as general economic and
market conditions, (iii) the company's responses to the COVID-19 pandemic, (iv) future business strategies, (v) expected savings and synergies
(including from the LaunchPad initiative and from acquisitions), and (vi) opportunities for future growth.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company’s
control, including without limitation, the trading price of the company’s stock, competitive actions and other unforeseen changes and general
uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including
changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or
recommendations, federal, state, and local government responses to the COVID-19 pandemic, the impact of global geopolitical events, the
effect of public opinion on the company’s reputation, adverse results in material litigation matters, the impact of changes in tax laws and
regulations, failure to maintain or develop customer relationships, the company's ability to develop or acquire new products and adapt to
technological changes, failure in information technology, systems or data security, the impact of potential losses under repurchase
agreements, adverse weather conditions, the number of revenue days in a financial period, employee relations, personnel costs, inflation, and
the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect
the company’s ability to implement the company’s business strategy and actual results could differ materially from those suggested by these
forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-
looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and
uncertainties that could affect operating and financial results is included in the company’s most recent Annual Report on Form 10-K and
subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company’s other filings with the SEC. The
Preview truncated — download the full document for the complete content.
conference
29 Pages
investor_presentation
24 Pages
Unknown
Tonix Pharmaceuticals TNX-1500 Transplant & Autoimmune 2024
investor_presentationinvestor_presentation
25 Pages
Tonix Pharmaceuticals Holding Corp.